FILING ANALYSIS · MONDAY, NOVEMBER 16

Aptevo Therapeutics Inc. APVO — 8-K: Results of Operations and Financial Condition

positive

Aptevo Therapeutics reports a 79% remission rate for Mipletamig in high-risk TP53-mutated AML, nearly double the historical benchmark, and announces progress in optimizing treatment tolerability and advancing its next-generation cancer treatment pipeline.

The filing

8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+